PATENT #14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

he Application of: Richard E. Olson

CASE NO.: PH-7076-A

APPLICATION NO.: 09/505,788

GROUP ART UNIT: 1624

FILED: FEBRUARY 17, 2000

EXAMINER: B. COLEMAN

FOR: SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith; with the following exception: acknowledging the Examiner's direct request US patent references, WO and EP publications have been cited but not provided in hard copy because they are already readily available to the Examiner.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880.

There are no listed references which are not in the English language or do not contain an English language abstract.

Respectfully submitted,

Bristol-Myers Squibb Company

P.O. Box 4000

Princeton, NJ 08543-4000

Scott K. Larsen, Ph. D., J.D.

Registration No. 38,532 Telephone: 302-467-5261

SEP 3 0 2002 CENTER 1600/2900